ReviewDiagnostics (Basel, Switzerland)2023
Diagnostic Predictors of Immunotherapy Response in Head and Neck Squamous Cell Carcinoma.
Review in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Computational and AI-Enabled Imaging Biomarkers for Predicting and Assessing Immunotherapy Response in Oral Squamous Cell Carcinoma: A Systematic Review with Functional Meta-Synthesis.Medical sciences (Basel, Switzerland) · 2026Pooled it
- Review
- Noninvasive Characterization of Tumor Heterogeneity in HNSCC: From Clinical Utility to Biological Correlates.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- Predictive Value of EGFR Expression for the Efficacy of Near-Infrared Photoimmunotherapy in Head and Neck Cancer.JMA journal · 2026Article
- The biological characteristics of tertiary lymphoid structures in head and neck cancer.Frontiers in immunology · 2026Review
- Spatial characterization of tertiary lymphoid structures as predictive biomarkers for immune checkpoint blockade in head and neck squamous cell carcinoma.Oncoimmunology · 2025Article
- Tumor-Informed ctDNA Assay to Predict Outcome in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated with PD-1 Inhibitor.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Induced B cell receptor diversity predicts PD-1 blockade immunotherapy response.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Immunotherapy in recurrent/metastatic head and neck squamous cell carcinoma: PD-L1 and beyond.Pathologica · 2025Review
- Article
- Identifying factors for pembrolizumab eligibility in head and neck cancer.Journal of cancer research and clinical oncology · 2025Article
- Malignant and Benign Head and Neck Tumors of the Pediatric Age: A Narrative Review.Current pediatric reviews · 2025Review
- Clinical and histopathological features of advanced cutaneous squamous cell carcinoma with varying responses to cemiplimab.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025Article
- Immune Cell Densities Predict Response to Immune Checkpoint-Blockade in Head and Neck Cancer.medRxiv : the preprint server for health sciences · 2024Article
- Serum Albumin as an Independent Predictor of Long-Term Survival in Patients with Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab.Journal of clinical medicine · 2024Article
- Mechanisms of Resistance and Therapeutic Perspectives in Immunotherapy for Advanced Head and Neck Cancers.Cancers · 2024Review
- Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy.Frontiers in oncology · 2024Review
- Head and Neck Squamous Cell Carcinoma Vaccine: Current Landscape and Perspectives.Current issues in molecular biology · 2023Review
- Baseline Values of Circulating IL-6 and TGF-β Might Identify Patients with HNSCC Who Do Not Benefit from Nivolumab Treatment.Cancers · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Programmed cell death ligand-1 (PD-L1) binds PD-1 on CD
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.